Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Accelerated Development
9%
C57BL
9%
Diabetes Mellitus Complications
9%
Diabetic
9%
Diabetic Kidney Disease
100%
Diabetic Nephropathy
9%
Downstream Signaling
9%
EGFR Inhibitors
9%
End-stage Renal Disease
9%
ErbB4
27%
Erlotinib
9%
Future Therapeutics
9%
Glomerular Function
9%
Glomerular Injury
36%
Glomerulopathy
18%
Glomerulus
27%
Hyperglycemia
9%
Inflammation
9%
Kidney Disease
9%
Knock-in Mouse Model
9%
Knockout Animals
18%
Low-dose Lipopolysaccharide
9%
Major Complications
9%
Mechanistic Understanding
9%
MiR-146
9%
MiR-146a
100%
Myeloid Cells
9%
Negative Regulator
9%
Podocyte
100%
Podocyte Injury
100%
Protective Behavior
9%
Proteinuria
36%
Report Generation
9%
Selective Deletion
9%
Smad3
9%
Streptozotocin
9%
Wild Mice
18%
Medicine and Dentistry
C57BL/6
8%
Complications of Diabetes Mellitus
8%
Diabetic Nephropathy
100%
EGFR Inhibitors
8%
End Stage Renal Disease
8%
Epidermal Growth Factor Receptor
8%
Erlotinib
8%
Glomerulopathy
16%
Glomerulus
25%
Hyperglycemia
8%
In Vitro
8%
Kidney Dysfunction
8%
Knockout Mouse
8%
Lipopolysaccharide
8%
Low Drug Dose
8%
microRNA 146a
100%
Myeloid Cell
8%
Podocyte
100%
Proteinuria
33%
Streptozocin
8%
Upregulation
8%
Biochemistry, Genetics and Molecular Biology
Epidermal Growth Factor Receptor
16%
Erlotinib
8%
Hyperglycemia
8%
Knockout Mouse
8%
Lipopolysaccharide
8%
Low Drug Dose
8%
MicroRNA
100%
Myeloid
8%
Podocyte
100%
Streptozotocin
8%
Upregulation
8%
Wild Type Mouse
16%
Immunology and Microbiology
Glomerulus
25%
In Vitro
8%
Knockout Mouse
8%
Low Drug Dose
8%
Myeloid
8%
Podocyte
100%
Upregulation
8%
Wild Type Mouse
16%